Chemotherapy and Radiotherapy Sequencing in Advanced Breast Cancer
Author Information
Author(s): Piroth Marc D, Pinkawa Michael, Gagel Bernd, Stanzel Sven, Asadpour Branka, Eble Michael J
Primary Institution: RWTH Aachen University Hospital
Hypothesis
What is the optimal sequence of chemotherapy and radiotherapy in patients with locoregional advanced breast cancer after mastectomy?
Conclusion
There is no clear advantage for any specific sequence of chemotherapy and radiotherapy in breast cancer therapy.
Supporting Evidence
- 5-year overall survival rates were 53.2% for sequential treatment, 38.1% for sandwich treatment, and 64.2% for simultaneous treatment.
- The study found no independent impact of treatment sequence on overall survival or disease-free survival.
- Acute and late toxicity showed no significant differences among the three treatment groups.
Takeaway
Doctors are trying to figure out the best order to give treatments for breast cancer, but so far, it seems like it doesn't really matter which order you choose.
Methodology
This study analyzed 212 patients with stage III breast cancer who received adjuvant chemotherapy and radiotherapy after mastectomy, comparing different treatment sequences.
Potential Biases
The distribution of patient and tumor-related parameters was unbalanced among the treatment groups.
Limitations
The study is retrospective and may have imbalances in patient characteristics across treatment groups.
Participant Demographics
The median age of participants was 64 years, with a range from 34 to 92 years.
Statistical Information
P-Value
p = 0.04 for overall survival, p = 0.03 for disease-free survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website